Dual-Payload ADCs to Enhance Anti-Tumor Immune Response and Overcome Payload Resistance
- Utilizing an innovative cell-free platform to create site-selective, high DAR, novel dual-payload ADCs with favorable pharmacokinetics
- Showcasing dual-payload ADCs with superior preclinical in vitro and in vivo efficacy to overcome acquired single-payload resistance
- Demonstrating an immunostimulatory-cytotoxin dual-payload ADC with enhanced efficacy and therapeutic potential